Novel maintains close partnerships with affiliated companies that can serve, augment, extend, or diversify our capabilities as a drug developer, manufacturer, or distributor. These partnerships are designed to create value for our customers and provide a platform for future growth. Key partnerships include:

GAVIS Pharmaceuticals allows us to extend our capabilities beyond drug development and manufacturing to include marketing and distribution – which makes us a full-service pharmaceutical partner for companies with an interest in challenging, high-barrier-to-entry products.

Wintac Limited is majority-owned by Novel, and currently manufactures seven different injectable and ophthalmic products in its 130,000-square-foot, FDA-approved facility. Planned expansion in 2015 will add another 60,000 square feet and five additional manufacturing lines for similar specialty products. In addition, Wintac contract manufactures products for a range of brand and generic pharmaceutical companies.